The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy
Abstract During the last decade, multiple clinical trials for Duchenne muscular dystrophy (DMD) have focused on the induction of dystrophin expression using different strategies. Many of these trials have reported a clear increase in dystrophin protein following treatment. However, the low levels of...
Main Authors: | Dominic Scaglioni, Francesco Catapano, Matthew Ellis, Silvia Torelli, Darren Chambers, Lucy Feng, Matthew Beck, Caroline Sewry, Mauro Monforte, Shawn Harriman, Erica Koenig, Jyoti Malhotra, Linda Popplewell, Michela Guglieri, Volker Straub, Eugenio Mercuri, Laurent Servais, Rahul Phadke, Jennifer Morgan, Francesco Muntoni |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Acta Neuropathologica Communications |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40478-020-01106-1 |
Similar Items
-
A high–throughput digital script for multiplexed immunofluorescent analysis and quantification of sarcolemmal and sarcomeric proteins in muscular dystrophies
by: Dominic Scaglioni, et al.
Published: (2020-04-01) -
The Interplay of Mitophagy and Inflammation in Duchenne Muscular Dystrophy
by: Andrea L. Reid, et al.
Published: (2021-07-01) -
State-of-the-art Advances in Duchenne Muscular Dystrophy
by: Henriette Van Ruiten, et al.
Published: (2017-03-01) -
Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
by: Maaike van Putten, et al.
Published: (2014-01-01) -
Natural history of Duchenne muscular dystrophy
by: Qing KE, et al.
Published: (2015-05-01)